17 July 2018
Welcome Dr. Shuxing Zhang to the Editorial Board of Non-Coding RNA
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are pleased to announce that Dr. Shuxing Zhang from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) has joined the Editorial Board of the journal Non-Coding RNA (ISSN 2311-553X). Dr. Zhang is an internationally recognized leader in computational modeling and drug discovery, and we firmly believe that his expertise will be a worthwhile addition to our esteemed group of experts.
Dr. Shuxing Zhang graduated from Peking University (Beijing, China) and completed his Ph.D. at the University of North Carolina (Chapel Hill, NC, USA) in the School of Pharmacy.
Currently, Dr. Zhang is leading the Intelligent Molecular Discovery Laboratory at the University of Texas MD Anderson Cancer Center. His research focuses on the development of novel computational strategies and frameworks for protein and RNA modeling, with a strong interest in targeted and personalized cancer therapy. Using his unique platform, Dr. Zhang has developed numerous therapeutic agents currently at the different stages of preclinical, Phase I, and Phase II clinical trials. His investigations involve a variety of targets, such as EGFR, Skp2, Akt, microRNAs, and lncRNAs. To date, Dr. Zhang has implemented various novel methods based on artificial intelligence, cheminformatics, molecular docking, and scoring functions (just to name a few) for drug discovery and development.
Dr. Zhang believes that RNA modeling, in particular accurate ncRNA structure prediction, is an area with significant challenges that needs a great deal of collective effort from the community. Such studies could have a tremendous impact on non-coding RNA biology and their implication in human health, and thus publications in this area should be encouraged to advance the field.